ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?

N. O'Neill, T. Zhang, X. Cheng, W. Sun, G. Braileanu, I. Tatarov, W. Hassanein, A. Azimzadeh, R. Pierson.

University of Maryland School of Medicine, Baltimore, MD

Meeting: 2017 American Transplant Congress

Abstract number: C298

Keywords: Co-stimulation, Immunosuppression, Monoclonal antibodies, Preclinical trails

Session Information

Session Name: Poster Session C: Tolerance/Immune Regulation

Session Type: Poster Session

Date: Monday, May 1, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Purpose: Inducible costimulator (ICOS) on T cells enhances basic T cell responses to foreign antigen, and increased ICOS expression is detected in association with pathogenic alloimmunity in αCD40-treated non-human primate (NHP) recipients of cardiac (and renal) allografts. We asked whether ICOS-Ig treatment timed to anticipate ICOS upregulation prolongs survival or attenuates pathogenic alloimmunity in a NHP cardiac model.

Methods: Cynomolgus heterotopic cardiac allograft recipients were treated with αCD40 (2C10R4, n=9). ICOS-Ig was given to three recipients (αCD40+ICOS-Ig) Q3-4 days at 5-10 mg/kg IV from D63 (ICOS expression is detected in graft T cells with 2C10R4 treatment) until D90-110. Acute rejection (ISHLT score) and chronic allograft vasculopathy (CAV score) severity were quantified in protocol biopsies and explanted grafts using published scoring systems. Both antidonor alloantibody production and peripheral blood T effector memory (EM: CD8+CD28–) phenotype were characterized using flow cytometry.

Results: Allograft median survival time (MST) was similar with αCD40+ICOS-Ig (120 days, range 120-125) and αCD40 monotherapy (124, 89-178, p=0.6). Peak ICOS-Ig levels generally exceeded a 100 [micro]g/mL target, although trough ICOS-Ig levels were unexpectedly low (<1 [micro]g/mL) despite progressive dose escalation. αCD40 and αCD40+ICOS-Ig had similar kinetics of alloantibody production, ISHLT (1.2±0.4 vs 1.7±0.6 at 3 months), and CAV scores (1.19±0.6 vs 1.34±0.33 at 3 months). Graft rejection was consistently associated with both IgM and IgG alloantibody production. From D63-D110, the number of CD8+ TEM cells were similar with αCD40+ICOS-Ig (466±67) and αCD40 (570±82, p=0.3).

Conclusions: The addition of the ICOS-Ig reagent as used here did not yield synergy with αCD40 or modulate surrogate markers of pathogenic alloimmunity, confirming prior observations in an NHP renal allograft model using an induction approach. Our findings suggest that alternative strategies to target pathogenic features of the ICOS/ICOS-L pathway should be prioritized in transplant models.

CITATION INFORMATION: O'Neill N, Zhang T, Cheng X, Sun W, Braileanu G, Tatarov I, Hassanein W, Azimzadeh A, Pierson R. Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade? Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

O'Neill N, Zhang T, Cheng X, Sun W, Braileanu G, Tatarov I, Hassanein W, Azimzadeh A, Pierson R. Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade? [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/does-blockade-of-icosicos-l-pathway-act-synergistically-with-cd40-costimulation-pathway-blockade/. Accessed May 8, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences